Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166341 · ClinicalTrials.gov registry record
Accuracy Verification of the INVOS PM7100
A clinical trial of Tissue Oxygenation, sponsored by Medtronic - MITG.
- Active
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT07166341: Active study of Tissue Oxygenation, sponsored by Medtronic - MITG.
NCT07166341 is a study of Tissue Oxygenation that is active but no longer recruiting, run by Medtronic - MITG. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166341, a study of Tissue Oxygenation, is active but no longer recruiting, sponsored by Medtronic - MITG.
- ACTIVE NOT RECRUITING
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, observational, pre-market, verification study to confirm accuracy of the INVOS 7100 system in compliance with ISO 80601-2-85:2021 standard
Primary Outcome
Performance assessed by comparing INVOS™ rSO2 to the calculated global field saturation (fSO2) value obtained from simultaneous arterial and jugular venous blood samples during normocapnia.
Conditions Studied
Interventions
- DEVICE Observational
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2026-04-24 |
What the registry record for NCT07166341 still lists
NCT07166341 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 1 condition, with Tissue Oxygenation appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT07166341 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07166341 about?
NCT07166341 is a clinical study titled "Accuracy Verification of the INVOS PM7100". Prospective, observational, pre-market, verification study to confirm accuracy of the INVOS 7100 system in compliance with ISO 80601-2-85:2021 standard
What is the current status of trial NCT07166341?
This trial is currently active not recruiting. The enrollment target is 48 participants. The study started on 2025-09-29. Estimated completion is 2026-04-24.
What conditions does trial NCT07166341 study?
This clinical trial studies the following conditions: Tissue Oxygenation.
What interventions are being tested in trial NCT07166341?
The interventions under investigation include: Observational (DEVICE).
Who is sponsoring clinical trial NCT07166341?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07166341 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI